Potential of imaging biomarkers for characterization of renal masses

Despite recent advances in therapeu-tic options, renal cell carcinoma (RCC) remains a challenging clinical problem. RCC represents 90% of all primary adult renal carcinomas. RCC is a heterogeneous disease and includes multiple subtypes that differ in their pathology, clinical behavior and genetic expression patterns

[1]  A. Scott,et al.  Functional imaging of renal cell carcinoma , 2010, Nature Reviews Urology.

[2]  I. Gill,et al.  Clinical practice. Small renal mass. , 2010, The New England journal of medicine.

[3]  S. L. Bridal,et al.  Clinical relevance of contrast-enhanced ultrasound in monitoring anti-angiogenic therapy of cancer: current status and perspectives. , 2010, Critical reviews in oncology/hematology.

[4]  J. Hajdenberg,et al.  Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America , 2010, Cancer.

[5]  J. Haanen,et al.  Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib , 2010, British Journal of Cancer.

[6]  O. Calvo,et al.  Renal cell carcinoma: complete response. , 2010, Anti-cancer drugs.

[7]  R. García-Campelo,et al.  Renal cell carcinoma: complete pathological response in a patient with gastric metastasis of renal cell carcinoma. , 2010, Anti-cancer drugs.

[8]  Shetal N Shah,et al.  Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. , 2010, AJR. American journal of roentgenology.

[9]  Wanling Xie,et al.  Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  S. Horenblas,et al.  Scanning with 18F-FDG-PET/CT for detection of pelvic nodal involvement in inguinal node-positive penile carcinoma. , 2009, European urology.

[11]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[12]  S. Signoretti,et al.  Tissue biomarkers in renal cell carcinoma: Issues and solutions , 2009, Cancer.

[13]  C. Nanni,et al.  11C-Acetate PET for Early Prediction of Sunitinib Response in Metastatic Renal Cell Carcinoma , 2009, Tumori.

[14]  R. Wahl,et al.  From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors , 2009, Journal of Nuclear Medicine.

[15]  H. Moch,et al.  Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability. , 2009, European urology.

[16]  Jong Wook Park,et al.  Significance of 18F‐fluorodeoxyglucose positron‐emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma , 2009, BJU international.

[17]  E. Hindié,et al.  18F-FDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: preliminary study. , 2009, Cancer biotherapy & radiopharmaceuticals.

[18]  John O. Prior,et al.  Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[20]  R. Uzzo,et al.  Excise, ablate or observe: the small renal mass dilemma--a meta-analysis and review. , 2008, The Journal of urology.

[21]  Sanjiv S Gambhir,et al.  US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice. , 2008, Radiology.

[22]  N. Rofsky,et al.  MR classification of renal masses with pathologic correlation , 2008, European Radiology.

[23]  T. Lebret,et al.  Percutaneous core biopsy for renal masses: indications, accuracy and results. , 2007, The Journal of urology.

[24]  E. Schiffer.  Biomarkers for prostate cancer , 2007, World Journal of Urology.

[25]  H. Hollema,et al.  In Vivo VEGF Imaging with Radiolabeled Bevacizumab in a Human Ovarian Tumor Xenograft , 2007, Journal of Nuclear Medicine.

[26]  J. Humm,et al.  Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. , 2007, The Lancet. Oncology.

[27]  Mitchell D Schnall,et al.  Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Assessing Tumor Vascularity and Vascular Effects of Targeted Therapies in Renal Cell Carcinoma , 2007, Clinical Cancer Research.

[28]  P. Choyke,et al.  Identification of the Genes for Kidney Cancer: Opportunity for Disease-Specific Targeted Therapeutics , 2007, Clinical Cancer Research.

[29]  G. Parker,et al.  DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents , 2007, British Journal of Cancer.

[30]  A. Ravaud,et al.  PET Scans for Decision-Making in Metastatic Renal Cell Carcinoma: A Single-Institution Evaluation , 2007, Oncology.

[31]  A. Scott,et al.  Fluorine-18 Fluorothymidine: A New Positron Emission Radioisotope for Renal Tumors , 2006, Clinical nuclear medicine.

[32]  Linda Chami,et al.  To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound. , 2006, European journal of cancer.

[33]  J. Lam,et al.  G250: A carbonic anhydrase IX monoclonal antibody , 2005, Current oncology reports.

[34]  Eric P Tamm,et al.  CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. , 2004, AJR. American journal of roentgenology.

[35]  V. Ravery,et al.  Preoperative imaging in renal cell cancer , 2004, World Journal of Urology.

[36]  G. Lindeman,et al.  Complete radiological and metabolic response of metastatic renal cell carcinoma to SU5416 (semaxanib) in a patient with probable von Hippel-Lindau syndrome. , 2004, Urologic oncology.

[37]  H. Bensadoun,et al.  Efficiency of [18F]FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[38]  S. Berlangieri,et al.  Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma. , 2001, The Journal of urology.

[39]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[40]  M. Terris,et al.  Positron emission tomography detection of osseous metastases of renal cell carcinoma not identified on bone scan. , 2000, Urology.

[41]  J L Warren,et al.  Rising incidence of renal cell cancer in the United States. , 1999, JAMA.

[42]  G. Denardo,et al.  Trials and tribulations: oncological antibody imaging comes to the fore. , 1997, Seminars in nuclear medicine.

[43]  Novick Ac.  Current surgical approaches, nephron-sparing surgery, and the role of surgery in the integrated immunologic approach to renal-cell carcinoma. , 1995 .

[44]  A. Novick.  Current surgical approaches, nephron-sparing surgery, and the role of surgery in the integrated immunologic approach to renal-cell carcinoma. , 1995, Seminars in oncology.